Drugs / GLUCAGON-LIKE PEPTIDE II

Trials 4 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT03682172 May → Aug 2018 gallbladder disorder Steno Diabetes Center Copenhagen Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01573286 Jan 2012 → Aug 2014 chronic intestinal failure, short bowel syndrome Alberta Children's Hospital Terminated No outcome recorded
Phase 31 trial
Phase 3 NCT01958775 Mar 2012 → Jun 2014 hyperlipidemia University Health Network, Toronto Completed No outcome recorded
Phase not applicable1 trial
NCT00273000 Jan 2006 → ? Glostrup University Hospital, Copenhagen Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT06194955 Comparator Jan 2023 → Dec 2025 hyperproglucagonemia University of Copenhagen Completed No outcome recorded
NCT00673751 Comparator short bowel syndrome Glostrup University Hospital, Copenhagen Unknown No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as GLUCAGON-LIKE PEPTIDE II ChEMBL registry synonym — accepted as the source's own label CHEMBL4297958
Known as 1-33-glucagon-like peptide ii ChEMBL registry synonym — accepted as the source's own label CHEMBL4297958
Known as GLP-2 GLP-2 (1-33) is a naturally occurring peptide which is important in controlling the function of the intestine.” NCT01573286
5

NCT00273000

NCT06194955

NCT01958775

NCT00673751

NCT03682172

Known as Glp-2 (1-33) ChEMBL registry synonym — accepted as the source's own label CHEMBL4297958
Known as Glp-2 (human) ChEMBL registry synonym — accepted as the source's own label CHEMBL4297958
Known as Glucagon like peptide-2 “The study will investigate the effect of the incretin hormone glucagon-like peptide 2 (GLP-2) on postprandial gallbladder motility in young, healthy, male subjects.” NCT03682172
2

“Drug: Glucagon like peptide-2NCT01573286

NCT01573286

Known as Glucagon-like Peptide “The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome” NCT00673751
Modality Peptide “GLP-2 (1-33) is a naturally occurring peptideNCT01573286
Route Intravenous “administered intraveneous GLP-2” NCT00273000